Summary
Two adult female cebus apella monkeys with persistent tardive dyskinesia (TD) were given acute i.m. injections of reference neuroleptics (chlorpromazine, haloperidol, thioridazine, and clozapine) or of potential new antipsychotic agents (MJ 13859-1 and MJ 13980-1). The drugs were assessed for their ability to modify TD symptoms or to produce acute neurologic reactions. Effects of three doses of MJ 13859-1 administered orally were also examined. At the doses used, thioridazine and clozapine had little or no effect. Chlorpromazine, haloperidol, MJ 13859-1 and MJ 13980-1 reduced or abolished TD and concomitantly produced hypokinesia, akinesia, mask expression, trembling, and reduced response to stimuli. Haloperidol also produced a mildly abnormal posture. In addition to the above effects, MJ 13859-1 also produced “slow motion” movement, sustained bizarre postures, sudden falls, and episodes of severe rigidity with trembling.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bedard, P., Delean, J., Lafleur, J., Larochelle, L.: Haloperidol-induced dyskinesias in the monkey. J. Can. Sci.4, 197–201 (1977).
Domino, E. F., Kovacic, B.: Monkey models of tardive dyskinesia. Mod. Probl. Pharmacopsychiat.21, 21–33 (1983).
Gelenberg, A. J., Doller, J. C.: Clozapine versus chlorpromazine for the treatment of schizophrenia: Preliminary results from a double blind study. J. Clin. Psychiat.40, 238–240 (1979).
Gunne, L. M., Bárány, S.: Haloperidol-induced tardive dyskinesia in monkeys. Psychopharmacol.50, 237–240 (1976).
Gunne, L. M., Bárány, S.: A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesia. Psychopharmacol.63, 195–198 (1979).
Hemphill, R. E., Pascoe, F. D., Zabow, T.: An investigation of clozapine in the treatment of acute and chronic schizophrenia and gross behavior disorders. S. Afr. Med. J.49, 2121–2125 (1975).
Kovacic, B., Domino, E. F.: A monkey model of tardive dyskinesia (TD): Evidence that reversible TD may turn into irreversible TD. J. Clin. Psychopharmacol.5, 305–307 (1982).
Kovacic, B., Domino, E. F.: Fluphenazine induced acute and tardive dyskinesia in monkeys. Psychopharmacol.84, 310–314 (1984).
Kovacic, B., Ruffing, D. M., Stanley, M.: Effects of neuroleptics and of potential new antipsychotic agents on monkeys with tardive dyskinesia. Poster presented at the 38th annual convention of the Society of Biological Psychiatry, April–May, New York, N.Y. (1983).
Liebman, J., Neale, R.: Neuroleptic-induced acute dyskinesias in squirrel monkeys: Correlation with propensity to cause extrapyramidal side effects. Psychopharmacol.68, 25–29 (1980).
McKinney, W. T., Moran, E. C., Kraemer, G. W., Prange, Jr., A. J.: Long-term chlorpromazine in rhesus monkeys: Production of dyskinesias and changes in social behavior. Psychopharmacol.72, 35–39 (1980).
Physicians' Desk Reference: Medical Economics Company, Inc., Oradell, New Jersey (1983).
Psychopharmacology Research Branch, National Institute of Mental Health: Development of a dyskinetic movement scale. Early Clinical Drug Evaluation Unit Intercom.4, 3–6 (1975).
Riblet, L. A., Eison, M. S., Taylor, D. P., Temple, Jr., D. L., Yevich, J. P.: Pharmacologic profile of a potential antipsychotic agent: MJ 13859-1. Soc. for Neurosci. Abstracts8, 470 (1982).
Riblet, L. A., Taylor, D. P., Eison, M. S., Temple, Jr., D. L., Yevich, J. P.: A promising antipsychotic agent with no predicted potential for extrapyramidal liability. Fed. Proc.42, 1153 (1983).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kovacic, B., Ruffing, D. & Stanley, M. Effect of neuroleptics and of potential new antipsychotic agents (MJ 13859-1 and MJ 13980-1) on a monkey model of tardive dyskinesia. J. Neural Transmission 65, 39–49 (1986). https://doi.org/10.1007/BF01249610
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01249610